Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486507 | 0.78 | MCL1 (0.45) | MCL1ALOX5 | |
| SCHEMBL28120185 | 0.77 | MCL1 (0.63) | MCL1MEN1KMT2AALOX5KDM4E | |
| SCHEMBL6486862 | 0.76 | ALDH1A1 (0.46) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL6476491 | 0.75 | SMN1; SMN2 (0.44) | MEN1KMT2ALMNASMN1; SMN2C5AR1 | |
| SCHEMBL6477614 | 0.74 | FFAR1 (0.47) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL6477222 | 0.71 | CYSLTR2 (0.42) | — | |
| SCHEMBL13152509 | 0.69 | KCNA3 (0.56) | MCL1ALOX5KDM4ELMNA | |
| SCHEMBL6473952 | 0.69 | FFAR1 (0.48) | C5AR1 | |
| SCHEMBL18152212 | 0.68 | MCL1 (0.64) | MCL1MEN1KMT2AALOX5KDM4E | |
| SCHEMBL11594992 | 0.67 | HSD17B1 (0.55) | MEN1KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933322-B2 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | WYETH | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216442-A1 | Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus | INSR, GPR119, SLC5A1 | MCL1 1257/4885MEN1 723/4885KMT2A 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.